Novartis AG ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $100.21
- Today's High:
- $101.045
- Open Price:
- $100.68
- 52W Low:
- $71.0039
- 52W High:
- $105.61
- Prev. Close:
- $99.24
- Volume:
- 1149856
Company Statistics
- Market Cap.:
- $205.25 billion
- Book Value:
- 2.5068
- Revenue TTM:
- $53.07 billion
- Operating Margin TTM:
- 27.69%
- Gross Profit TTM:
- $36.74 billion
- Profit Margin:
- 14.41%
- Return on Assets TTM:
- 7.86%
- Return on Equity TTM:
- 13.32%
Company Profile
Novartis AG ADR had its IPO on 1991-11-18 under the ticker symbol NVS.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Novartis AG ADR has a staff strength of 103,000 employees.
Stock update
Shares of Novartis AG ADR opened at $100.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $100.21 - $101.05, and closed at $100.66.
This is a +1.43% increase from the previous day's closing price.
A total volume of 1,149,856 shares were traded at the close of the day’s session.
In the last one week, shares of Novartis AG ADR have slipped by -0.06%.
Novartis AG ADR's Key Ratios
Novartis AG ADR has a market cap of $205.25 billion, indicating a price to book ratio of 3.2725 and a price to sales ratio of 3.7233.
In the last 12-months Novartis AG ADR’s revenue was $53.07 billion with a gross profit of $36.74 billion and an EBITDA of $20.03 billion. The EBITDA ratio measures Novartis AG ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Novartis AG ADR’s operating margin was 27.69% while its return on assets stood at 7.86% with a return of equity of 13.32%.
In Q2, Novartis AG ADR’s quarterly earnings growth was a positive 44.2% while revenue growth was a positive 6.5%.
Novartis AG ADR’s PE and PEG Ratio
- Forward PE
- 14.5349
- Trailing PE
- 27.5667
- PEG
- 5.7688
Its diluted EPS in the last 12-months stands at $3.6 per share while it has a forward price to earnings multiple of 14.5349 and a PEG multiple of 5.7688. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novartis AG ADR’s profitability.
Novartis AG ADR stock is trading at a EV to sales ratio of 3.9682 and a EV to EBITDA ratio of 6.6563. Its price to sales ratio in the trailing 12-months stood at 3.7233.
Novartis AG ADR stock pays annual dividends of $3.461 per share, indicating a yield of 3.53% and a payout ratio of 52.24%.
Balance sheet and cash flow metrics
- Total Assets
- $110.98 billion
- Total Liabilities
- $31.91 billion
- Operating Cash Flow
- $9.57 billion
- Capital Expenditure
- $996 million
- Dividend Payout Ratio
- 52.24%
Novartis AG ADR ended 2024 with $110.98 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $110.98 billion while shareholder equity stood at $51.85 billion.
Novartis AG ADR ended 2024 with $0 in deferred long-term liabilities, $31.91 billion in other current liabilities, 842000000.00 in common stock, $51.06 billion in retained earnings and $29.52 billion in goodwill. Its cash balance stood at $10.89 billion and cash and short-term investments were $11.17 billion. The company’s total short-term debt was $8,536,000,000 while long-term debt stood at $18.26 billion.
Novartis AG ADR’s total current assets stands at $33.49 billion while long-term investments were $2.43 billion and short-term investments were $289.00 million. Its net receivables were $9.54 billion compared to accounts payable of $5.35 billion and inventory worth $8.23 billion.
In 2024, Novartis AG ADR's operating cash flow was $9.57 billion while its capital expenditure stood at $996 million.
Comparatively, Novartis AG ADR paid $0.52 in dividends in 2024.
Other key metrics
- Current Trading Price
- $100.66
- 52-Week High
- $105.61
- 52-Week Low
- $71.0039
- Analyst Target Price
- $116
Novartis AG ADR stock is currently trading at $100.66 per share. It touched a 52-week high of $105.61 and a 52-week low of $105.61. Analysts tracking the stock have a 12-month average target price of $116.
Its 50-day moving average was $101.4 and 200-day moving average was $93.86 The short ratio stood at 2.76 indicating a short percent outstanding of 0%.
Around 0.4% of the company’s stock are held by insiders while 804% are held by institutions.
Frequently Asked Questions About Novartis AG ADR
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.